Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from ADCT

1 'Strong Buy' Russell 2000 Stock With 188% Upside Potential

As a part of the annual Russell Index reconstitution, this ‘Strong Buy’-rated penny stock is one of the new entrants to the Russell 2000 Index.

Barchart · Jul 2, 2024

HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications

ADC Therapeutics SA (NYSE:ADCT) presented updated efficacy and safety results from the Phase 2 trial of camidanlumab tesirine (Cami, formerly ADCT-301) in relapsed or refractory Hodgkin lymphoma. Cami demonstrated a 70.1% overall response rate (ORR), with a 33.3% complete response (CR) rate. From a safety perspective, eight of 117 patients developed Guillain-Barré syndrome…

Benzinga · Jun 13, 2022

Analyst Ratings for ADC Therapeutics

Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter:

Benzinga · May 10, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

RBC Capital Maintains Outperform Rating for ADC Therapeutics: Here's What You Need To Know

RBC Capital has decided to maintain its Outperform rating of ADC Therapeutics (NYSE:ADCT) and lower its price target from $34.00 to $30.00. Shares of ADC Therapeutics are trading down 1.34% over the last 24 hours, at $7.71 per share.

Benzinga · May 10, 2022

Earnings Outlook For ADC Therapeutics

ADC Therapeutics (NYSE:ADCT) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that ADC Therapeutics will report an earnings per share (EPS) of $-0.70.

Benzinga · May 6, 2022

How To Attend ADC Therapeutics Q1 2022 Earnings Conference Call

ADC Therapeutics (NYSE:ADCT) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. How to Attend ADC Therapeutics (ADCT) Conference Call Follow this link to access the live webcast.

Benzinga · May 4, 2022

Cantor Fitzgerald Cuts ADC Therapeutics Price Target On 'Repositioned Zynlonta Pipeline Strategy'

Following Q4 FY21 results, Cantor Fitzgerald has lowered the price target on ADC Therapeutics SA (NASDAQ: ADCT) to $26 from $45 and keeps an Overweight rating.

Benzinga · Mar 4, 2022

Read news from The Economist, FT, and more,
with one subscription

Recap: ADC Therapeutics Q4 Earnings

ADC Therapeutics (NYSE:ADCT) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · Mar 3, 2022

Earnings Preview For ADC Therapeutics

ADC Therapeutics (NYSE:ADCT) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate that ADC Therapeutics will report an earnings per share (EPS) of $-0.86.

Benzinga · Mar 2, 2022

ADC Therapeutics, Mitsubishi Tanabe Ink Zynlonta Licensing Pact In Japan

ADC Therapeutics SA (NYSE: ADCT) has

Benzinga · Jan 18, 2022

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Places

Japan

21,416 stories

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.